Last reviewed · How we verify
Robaxin (METHOCARBAMOL)
Robaxin (METHOCARBAMOL) is a small molecule muscle relaxant developed by AUXILIUM PHARMS LLC and currently owned by Hikma. It targets carbonic anhydrase 1 to treat muscle spasm with pain, spasticity, and tetanus adjunct treatment. Robaxin is an off-patent medication with 51 generic manufacturers, approved by the FDA in 1957. As a muscle relaxant, it is used to alleviate muscle spasms and associated pain. Key safety considerations include its potential for drowsiness and interactions with other medications.
At a glance
| Generic name | METHOCARBAMOL |
|---|---|
| Sponsor | Hikma |
| Drug class | Muscle Relaxant [EPC] |
| Target | Carbonic anhydrase 1 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
- Muscle Spasm with Pain
- Spasticity
- Tetanus Adjunct Treatment
Common side effects
- Anaphylactic reaction
- Angioneurotic edema
- Fever
- Headache
- Bradycardia
- Flushing
- Hypotension
- Syncope
- Thrombophlebitis
- Dyspepsia
- Jaundice
- Nausea and vomiting
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Plasma Relaxin Measurement Based on Endometrial Preparation for Embryo Transfer
- A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (PHASE2)
- Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection (PHASE4)
- Relaxin Therapy for Atrial Fibrillation (PHASE1,PHASE2)
- A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement (PHASE3)
- Intravenous Methocarbamol for Acute Pain After Spine Surgery
- A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 12390439 | 2044-10-09 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Robaxin CI brief — competitive landscape report
- Robaxin updates RSS · CI watch RSS
- Hikma portfolio CI